Hearing Aids May Help Thinking, but Dementia Prevention Is Unproven

The overall trial result limits the claim

Hearing aids may support thinking skills in some older adults, but the ACHIEVE trial does not establish that they prevent dementia. Its headline finding requires two statements: the randomized trial found no statistically significant cognitive benefit across all participants over three years; a prespecified analysis suggested a benefit in one higher-risk subgroup. Reporting either statement alone may leave readers with the wrong impression. The 2023 Lancet paper provides the essential distinction.

The widely repeated 48% figure describes less deterioration on a standardized global cognitive score in that subgroup. It does not mean 48% fewer dementia diagnoses, a 48% improvement in memory, or a 48% reduction in an individual reader’s risk. Those interpretations substitute different outcomes for the one researchers measured. A percentage can be numerically accurate while the sentence surrounding it makes an unsupported clinical claim.

That distinction may matter especially in healthy-aging coverage, where an accessible device can acquire a much larger reputation than its trials justify. A hearing aid may help someone follow a conversation without changing the course of a neurodegenerative disease. Conversely, an uncertain dementia-prevention claim does not erase the potential value of easier communication. The sensible editorial question is which outcome a particular study actually supports.

For readers considering hearing care, the most defensible framing is therefore conditional: comprehensive hearing support may offer cognitive benefits for some people, while dementia prevention remains unproven by this trial. There is no need to describe the device as a rejuvenation technology to explain why researchers consider the question important.

What ACHIEVE actually compared

ACHIEVE enrolled 977 community-dwelling adults aged 70–84 with untreated hearing loss and without substantial cognitive impairment. Researchers randomly assigned participants to a hearing intervention or a health-education comparison. The primary endpoint was change over three years in a global score assembled from cognitive tests. These design details, documented in the National Heart, Lung, and Blood Institute’s study record, define the population and question being studied.

The hearing arm involved fitted hearing aids, four initial one-hour sessions, and reinforcement of device use and communication strategies at six-month intervals. The comparison arm also received scheduled education and follow-up. That makes the experiment more informative than simply comparing people who choose to buy hearing aids with people who do not: access to care, motivation, and other personal differences may otherwise influence the comparison.

However, the package creates a separate interpretation problem. Its results may reflect amplification, professional fitting, instruction, communication strategies, or their combination. A product advertisement that attributes the trial’s findings entirely to the hardware skips over those possibilities. The experiment was not designed to identify the contribution of each component or to rank commercial devices.

The practical implication is narrower than a shopping recommendation. Evidence from supported hearing rehabilitation may not transfer unchanged to an inexpensive device purchased without assistance, or to a premium device that remains unused. Neither price nor technical sophistication substitutes for demonstrating that a particular approach delivers the outcome being advertised.

A reader can apply a simple test to any claim based on ACHIEVE: does the claim identify the studied population, the complete intervention, the comparison, and the outcome? If it mentions only a hearing aid and a striking percentage, too much of the experiment may have disappeared from the explanation.

Why the subgroup result deserves careful attention

Participants came from two recruitment streams. One comprised 238 members of the long-running Atherosclerosis Risk in Communities study, known as ARIC; the other comprised 739 newly recruited volunteers. The National Institute on Aging’s explanation reports that the ARIC participants generally had more risk factors for cognitive deterioration than the new volunteers. The apparent cognitive benefit emerged in that higher-risk group.

In the primary publication, the estimated three-year cognitive deterioration in the ARIC hearing-intervention group was approximately 48% lower than in its comparison group. No corresponding benefit was detected in the newly recruited group. The subgroup analysis was prespecified, which gives it more credibility than an unexpected division selected only after examining favorable results. Nevertheless, the overall primary comparison remained statistically negative.

Those findings need not be logically inconsistent. As a statistical interpretation, an intervention could help a subset of participants while producing little detectable average difference in a larger mixed population. Another possibility is that subgroup estimates overstate a true effect through sampling variation. The observed pattern alone cannot settle how much each explanation contributes.

Prespecification matters because it reduces the opportunity to search through many divisions until something looks promising. It does not make a subgroup result immune to uncertainty. A smaller group provides a less precise basis for prediction, and an average group response does not identify which individual participants benefited. The distinction is particularly important when moving from a paper to a clinical conversation.

Nor does membership in an older cardiovascular cohort offer a ready-made eligibility rule for consumers. Someone with hypertension or diabetes should not infer that the 48% estimate applies personally. Establishing an individual treatment rule would require evidence that a reproducible set of characteristics predicts a meaningful benefit, preferably tested in another population.

The most useful next question is therefore whether further randomized work can reproduce the pattern and define its boundaries. Does benefit depend on baseline cognitive vulnerability, the degree of hearing difficulty, rehabilitation support, or another characteristic? These are proposals for testing, rather than conclusions already available from the subgroup percentage.

How hearing support might affect cognitive performance

Researchers have proposed several pathways connecting hearing difficulty with cognitive outcomes. Poorly encoded sound may increase the mental effort needed to understand speech; hearing difficulties may also reduce social engagement. Changes in brain structure are another proposed pathway. The NHLBI study background presents these as possible explanations for an observed association, rather than established proof of how hearing intervention works.

Consider the listening-effort hypothesis. If a person must repeatedly reconstruct missed words, a clearer signal might leave more attention available for following the meaning of a conversation. That is a plausible mechanism, but it does not establish that amplification changes the underlying processes of Alzheimer’s disease. Better access to information and slower disease progression are different hypotheses, even when both could influence a cognitive test result.

The device itself also has physical limits. The National Institute on Deafness and Other Communication Disorders explains that hearing aids amplify sound so surviving sensory cells can respond more effectively. They may improve speech comprehension in people with appropriate forms of hearing loss, but they do not recreate normal hearing or regenerate damaged inner-ear cells. Amplification should not be described as cellular repair.

These distinctions suggest a useful hierarchy for interpreting results: improved audibility, easier communication, better performance on a test, sustained everyday independence, and fewer dementia diagnoses. A study may support one level without establishing all the others. Moving upward requires measuring the additional outcome, rather than assuming that one favorable result carries through the whole chain.

Mechanistic language can itself become promotional when a plausible explanation is presented as an observed effect. Phrases such as reducing cognitive load may sound decisive, but the important question is whether investigators measured that pathway and showed that it accounted for the clinical result. Without that step, the mechanism remains a candidate explanation.

Social outcomes offer a separate reason for interest

A 2025 secondary analysis of ACHIEVE examined social isolation and loneliness over three years. Compared with health education, the hearing intervention was associated with retaining approximately one additional person in participants’ social networks, on average. The analysis also suggested favorable differences in network diversity, relationship quality, and loneliness measures. These findings come from the JAMA Internal Medicine report.

The loneliness difference was modest: the adjusted between-group difference in change was approximately 0.94 points on the UCLA loneliness scale. That estimate may indicate a small average effect; it does not suggest that hearing support eliminates loneliness. A numerical difference also needs interpretation in relation to what participants actually notice in daily life.

Social network size and loneliness describe different experiences. Someone may have frequent contact yet feel disconnected, while another person may prefer a small circle and feel satisfied. Measuring both is useful because a change in contact does not automatically establish a change in emotional experience. For an individual, the meaningful goal might be participating comfortably in an existing relationship rather than acquiring more contacts.

These social findings should not be presented as independent replication of the cognitive result. They arose from the same randomized study and addressed different outcomes. They also do not establish that improved social connection mediated any cognitive benefit. Demonstrating that pathway would require an analysis capable of separating the proposed mechanism from other explanations.

Still, the findings may broaden the conversation in a constructive way. A person’s ability to take part in family discussions or community activities can be worth evaluating on its own terms. Making every benefit depend on a future dementia diagnosis risks overlooking changes that may already matter to the person receiving care.

What readers can reasonably take into a hearing appointment

For someone considering hearing support, the evidence may justify discussing communication difficulties without expecting a dementia-prevention prescription. A useful starting point could be a concrete situation: struggling to follow several speakers, missing parts of telephone conversations, or finding an existing device uncomfortable. Such examples give a professional a functional problem to assess instead of an abstract promise about future brain health.

In the United States, the FDA explains that adults aged 18 or older with perceived mild to moderate hearing loss may buy over-the-counter hearing aids without a medical examination or hearing test. An audiological evaluation may nevertheless help establish the type and extent of difficulty. This access pathway does not make an over-the-counter product equivalent to the supported intervention studied in ACHIEVE.

The FDA also identifies trial periods, return conditions, warranties, maintenance, and professional support as relevant purchasing considerations. These details may be more useful to a prospective user than an unsupported claim about preventing dementia. A device’s value in practice may depend on whether it works in the situations that prompted the purchase and whether problems can be addressed.

The NIDCD notes that adjustment can take time and that fit, comfort, feedback, and the sound of one’s own voice may require attention. Its guidance also cautions against choosing solely by price. These are reasons to evaluate the service and the listening experience alongside the device, rather than treating a higher price as evidence of greater cognitive protection.

For a future prevention claim to become convincing, stronger evidence would need to address a harder question than short-term test performance: does hearing intervention reduce clinically meaningful cognitive impairment or dementia over an adequate follow-up period? Researchers would also need to show how well the findings apply outside the original trial population and support system.

An overall negative result should not be rewritten as universal success, and a promising subgroup result should not be discarded simply because it complicates the headline. Together, the findings support continued investigation and a measured discussion of possible benefits. They do not support a guarantee about dementia, a cure for neurodegeneration, or a claim that hearing devices reverse aging.

Frequently asked questions

Do hearing aids prevent dementia?

ACHIEVE does not establish dementia prevention. Research suggests possible cognitive benefits in some higher-risk older adults, but the overall three-year cognitive result was negative.

Does the 48% figure mean my dementia risk may fall by half?

No. It describes less deterioration in a cognitive test score within one prespecified subgroup, rather than a measured reduction in dementia diagnoses.

Can an over-the-counter device reproduce the trial’s results?

That remains uncertain. ACHIEVE tested fitted hearing aids with professional instruction and follow-up, so its findings may not transfer directly to an unsupported purchase.

This article summarises published research and is not medical advice. Consult your healthcare provider before changing your routine.